BioMarker Strategies Gets $1.7M in Private Investment | GenomeWeb

NEW YORK (GenomeWeb News) – BioMarker Strategies has raised $1.7 million through a private funding round that included the Abell Foundation, the Baltimore-based company said today.

BioMarker Strategies is developing a tumor biopsy processing and testing system called SnapPath that is intended to quickly analyze a solid sample at the point of biopsy. It also is developing a series of pathway-based, ex-vivo biomarker tests to help physicians make therapeutic decisions for cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."